NCT00052013View on ClinicalTrials.gov

Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

June 30, 2006

Conditions
Von Hippel-Lindau DiseaseCNS HemangioblastomaRetinal Hemangioblastoma
Interventions
DRUG

PTK787/ZK 222584

Trial Locations (2)

27710

Duke University Medical Center, Durham

02115

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY